Indian Immunologicals Limited (IIL), a leading vaccine manufacturer, launches India’s very first, indigenously developed gE deleted DIVA (Differentiated between Infected and Vaccinated Animal) marker vaccine against Infectious Bovine Rhinotracheitis (IBR) in Anand, Gujarat. IBR disease is endemic in India and is caused by Bovine Herpes Virus (BHV-1). In India incidence of IBR is above 32% and is estimated that the loss in productivity could be to the tune of ₹18000 Crores. There is no vaccine available in India and there is no specific treatment against this disease so far. Bearing this in mind, our scientists along with NDDB after years of research have developed India’s first vaccine for IBR”.